Glaukos Corporation (GKOS)
154.12
0.92 (0.60%)
At close: Feb 18, 2025, 3:59 PM
152.96
-0.75%
After-hours: Feb 18, 2025, 04:10 PM EST
undefined% (undefined)
| Bid | 148.78 |
| Market Cap | 8.50B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.93 |
| PE Ratio (ttm) | -52.6 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 157.14 |
| Volume | 441,624 |
| Avg. Volume (20D) | 549,218 |
| Open | 154.00 |
| Previous Close | 153.20 |
| Day's Range | 153.09 - 157.33 |
| 52-Week Range | 83.90 - 163.71 |
| Beta | undefined |
About GKOS
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stent...
Industry Medical - Devices
Sector Healthcare
IPO Date Jun 25, 2015
Employees 907
Stock Exchange NYSE
Ticker Symbol GKOS
Website https://www.glaukos.com
Analyst Forecast
According to 12 analyst ratings, the average rating for GKOS stock is "Strong Buy." The 12-month stock price forecast is $151, which is a decrease of -2.02% from the latest price.
Buy 83.33%
Hold 8.33%
Sell 8.33%
Next Earnings Release
Glaukos Corporation is scheduled to release its earnings on Feb 20, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+4.77%
Glaukos shares are trading higher after Citigroup ...
Unlock content with
Pro Subscription
3 months ago
-0.3%
Glaukos shares are trading lower. The company reported Q3 financial results.
